Changes to anti-JCV antibody levels in a Swedish national MS cohort

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 84, Issue 11, 2013, Pages 1199-1205

  Warnke, Clemens ^a,b   Ramanujam, Ryan ^a   Plavina, Tatiana ^c   Bergström, Tomas ^d   Goelz, Susan ^e   Subramanyam, Meena ^c   Kockum, Ingrid ^a   Rahbar, Afsar ^a   Kieseier, Bernd C ^b   Holmén, Carolina ^a   Olsson, Tomas ^a   Hillert, Jan ^a   Fogdell Hahn, Anna ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Department of Orthopedic Surgery   (Germany)

^c BIOGEN   (United States)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e ELAN PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GAMMA INTERFERON; INTERFERON; JC VIRUS ANTIBODY; NATALIZUMAB; UNCLASSIFIED DRUG; VIRUS ANTIBODY; MONOCLONAL ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; CHILD; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG SURVEILLANCE PROGRAM; FEMALE; HUMAN; IMMUNOASSAY; JC VIRUS; MALE; MULTIPLE SCLEROSIS; PREDICTION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RISK FACTOR; SCHOOL CHILD; SEROCONVERSION; SERODIAGNOSIS; SWEDEN; UPREGULATION; VALIDATION PROCESS; VARICELLA ZOSTER VIRUS; BLOOD; CYTOMEGALOVIRUS; EARLY DIAGNOSIS; IMMUNOLOGY; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MIDDLE AGED; POSTMARKETING SURVEILLANCE; VIROLOGY;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, VIRAL; CYTOMEGALOVIRUS; EARLY DIAGNOSIS; FEMALE; HERPESVIRUS 3, HUMAN; HUMANS; INTERFERONS; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PHARMACOVIGILANCE; PRODUCT SURVEILLANCE, POSTMARKETING; RISK FACTORS;

EID: 84885672676     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2012-304332     Document Type: Article

References (35)

1. Coisne C, Mao W, Engelhardt B. Cutting edge: natalizumab blocks adhesion but not initial contact of human T cells to the blood-brain barrier in vivo in an animal model of multiple sclerosis. J Immunol 2009;182:5909-13.
2. Rice GP, Hartung HP, Calabresi PA. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 2005;64:1336-42. (Pubitemid 40570497)
3. Clifford DB, De Luca A, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28. cases. Lancet Neurol 2010;9:438-46.
4. Kappos L, Bates D, Edan G, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 2011;10:745-58.
5. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006;354:924-33.
6. Sunyaev SR, Lugovskoy A, Simon K, et al. Adaptive mutations in the JC virus protein capsid are associated with progressive multifocal leukoencephalopathy (PML). PLoS Genet 2009;5:e1000368.
7. Gorelik L, Reid C, Testa M, et al. Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificity. J Infect Dis 2011;204:103-14.
8. Reid CE, Li H, Sur G, et al. Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients. J Infect Dis 2011;204:237-44.
9. Warnke C, Menge T, Hartung HP, et al. Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch Neurol 2010;67:923-30.
10. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010;68:295-303.
11. Goelz SE, Gorelik L, Subramanyam M. Assay design and sample collection can affect anti-John Cunningham virus antibody detection. Ann Neurol 2011;69:429-30; author reply 30-1.
12. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab- associated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366:1870-80.
13. Warnke C, Adams O, Hartung HP, et al. Risk stratification of progressive multifocal leukoencephalopathy under natalizumab: recommendations for JC virus serology. Nervenarzt 2011;82:1314-19.
14. Bozic C, Richman S, Plavina T, et al. Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol 2011;70:713-21.
15. Plavina T, Berman M, Njenga M, et al. Multi-site analytical validation of an assay to detect anti-JCV antibodies in human serum and plasma. J Clin Virol 2012;53:65-71.
16. Holmen C, Piehl F, Hillert J, et al. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. Mult Scler 2011;17:708-19.
17. Piehl F, Holmen C, Hillert J, et al. Swedish natalizumab (Tysabri) multiple sclerosis surveillance study. Neurol Sci 2011;31(Suppl 3):289-93.
18. Schmitz H, Doerr HW, Kampa D, et al. Solid-phase enzyme immunoassay for immunoglobulin M antibodies to cytomegalovirus. J Clin Microbiol 1977;5:629-34. (Pubitemid 8137876)
19. Grahn A, Studahl M, Nilsson S, et al. Varicella-Zoster Virus (VZV) Glycoprotein E Is a Serological Antigen for Detection of Intrathecal Antibodies to VZV in Central Nervous System Infections, without Cross-Reaction to Herpes Simplex Virus 1. Clin Vaccine Immunol 2011;18:1336-42.
20. Thomsson E, Persson L, Grahn A, et al. Recombinant glycoprotein E produced in mammalian cells in large-scale as an antigen for varicella-zoster-virus serology. J Virol Methods 2011;175:53-9.
21. Knowles WA, Pipkin P, Andrews N, et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 2003;71:115-23. (Pubitemid 37121921)
22. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007;357:1903-15. (Pubitemid 350074686)
23. Leite RP, Carmo-Fonseca M, Cabecadas J, et al. Differential expression of cell adhesion molecules in the functional compartments of lymph nodes and tonsils. Clin Mol Pathol 1995;48:M93-100.
24. Bonig H, Wundes A, Chang KH, et al. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood 2008;111:3439-41.
25. Jing D, Oelschlaegel U, Ordemann R, et al. CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function. Bone Marrow Transplant 2010;45:1489-96.
26. Saure C, Warnke C, Zohren F, et al. Natalizumab and impedance of the homing of CD34+ hematopoietic progenitors. Arch Neurol 2011;68:1428-31.
27. Warnke C, Smolianov V, Dehmel T, et al. CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus. Mult Scler 2011;17:151-6.
28. Zohren F, Toutzaris D, Klarner V, et al. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood 2008;111:3893-5.
29. Planas R, Jelcic I, Schippling S, et al. Natalizumab Treatment Perturbs Memory- and Marginal Zone-like B-cell Homing in Secondary Lymphoid Organs in Multiple Sclerosis. Eur J Immunol 2011;42:790-8.
30. Koopman G, Keehnen RM, Lindhout E, et al. Adhesion through the LFA-1 (CD11a/CD18)-ICAM-1 (CD54) and the VLA-4 (CD49d)-VCAM-1 (CD106) pathways prevents apoptosis of germinal center B cells. J Immunol 1994;152:3760-7. (Pubitemid 24111046)
31. Amanna IJ, Slifka MK. Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol Rev 2010;236:125-38.
32. Flo RW, Nilsen A, Voltersvik P, et al. Serum antibodies to viral pathogens and Toxoplasma gondii in HIV-infected individuals. Apmis 1993;101:946-52. (Pubitemid 24063736)
33. Vescovini R, Biasini C, Telera AR, et al. Intense antiextracellular adaptive immune response to human cytomegalovirus in very old subjects with impaired health and cognitive and functional status. J Immunol 2010;184:3242-9.
34. Ryschkewitsch CF, Jensen PN, Monaco MC, et al. JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab. Ann Neurol 2010;68:384-91.
35. Trampe AK, Hemmelmann C, Stroet A, et al. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology 2012;78:1736-42.